Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

被引：615

作者：

Walter, Steffen ^{[1
]}

Weinschenk, Toni ^{[1
]}

Stenzl, Arnulf ^{[2
]}

Zdrojowy, Romuald ^{[3
]}

Pluzanska, Anna ^{[4
]}

Szczylik, Cezary ^{[5
]}

Staehler, Michael ^{[6
]}

Brugger, Wolfram ^{[7
,8
]}

Dietrich, Pierre-Yves ^{[9
]}

Mendrzyk, Regina ^{[1
]}

Hilf, Norbert ^{[1
]}

Schoor, Oliver ^{[1
]}

Fritsche, Jens ^{[1
]}

Mahr, Andrea ^{[1
]}

Maurer, Dominik ^{[1
]}

Vass, Verona ^{[1
]}

Trautwein, Claudia ^{[1
]}

Lewandrowski, Peter ^{[1
]}

Flohr, Christian ^{[1
]}

Pohla, Heike ^{[10
,11
]}

Stanczak, Janusz J. ^{[12
]}

Bronte, Vincenzo ^{[13
]}

Mandruzzato, Susanna ^{[14
,15
]}

Biedermann, Tilo ^{[16
]}

Pawelec, Graham ^{[17
]}

Derhovanessian, Evelyna ^{[17
]}

Yamagishi, Hisakazu ^{[18
]}

Miki, Tsuneharu ^{[19
]}

Hongo, Fumiya ^{[19
]}

Takaha, Natsuki ^{[19
]}

Hirakawa, Kosei ^{[20
]}

Tanaka, Hiroaki ^{[20
]}

Stevanovic, Stefan ^{[21
]}

Frisch, Juergen ^{[1
]}

Mayer-Mokler, Andrea ^{[1
]}

Kirner, Alexandra ^{[1
]}

Rammensee, Hans-Georg ^{[21
]}

Reinhardt, Carsten ^{[1
]}

Singh-Jasuja, Harpreet ^{[1
]}

机构：

[1] Immat Biotechnol GmbH, Tubingen, Germany

[2] Univ Tubingen, Dept Urol, Tubingen, Germany

[3] Univ Med, Dept Urol & Urol Oncol, Wroclaw, Poland

[4] Uniwersytetu Med, Klin Chemiotherapii Nowotworow UM, Lodz, Poland

[5] Mil Inst Med, Dept Oncol, Warsaw, Poland

[6] Univ Munich, IZN, Munich, Germany

[7] Univ Freiburg, Schwarzwald Baar Klinikum, Dept Hematol Oncol & Immunol, Villingen Schwenningen, Germany

[8] Univ Freiburg, Acad Teaching Hosp, Villingen Schwenningen, Germany

[9] Univ Hosp Geneva, Ctr Oncol, Lab Tumour Immunol, Geneva, Switzerland

[10] Univ Munich, LIFE Ctr, Lab Tumor Immunol, Munich, Germany

[11] Helmholtz Ctr, Inst Mol Immunol, Munich, Germany

[12] Hosp Infect Dis, Mol Diagnost Lab, Warsaw, Poland

[13] Verona Univ Hosp, Dept Pathol & Diagnost, Verona, Italy

[14] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy

[15] IRCCS, IOV, Padua, Italy

[16] Univ Tubingen, Dept Dermatol, Tubingen, Germany

[17] Univ Tubingen, Med Res Ctr, Dept Internal Med 2, Tubingen, Germany

[18] Kyoto Prefectural Univ Med, Dept Surg, Kyoto 602, Japan

[19] Kyoto Prefectural Univ Med, Dept Urol, Kyoto, Japan

[20] Osaka City Univ, Dept Surg Oncol, Osaka 558, Japan

[21] Univ Tubingen, Dept Immunol, Tubingen, Germany

来源：

NATURE MEDICINE | 2012年 / 18卷 / 08期

关键词：

REGULATORY T-CELLS; COLONY-STIMULATING FACTOR; MYELOID SUPPRESSOR-CELLS; DENDRITIC CELLS; TUMOR-ANTIGEN; MELANOMA PATIENTS; HIGH-FREQUENCIES; PEPTIDE VACCINE; CUTTING EDGE; IDENTIFICATION;

D O I：

10.1038/nm.2883

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

IMA901 is the first therapeutic vaccine for renal cell cancer (RCC) consisting of multiple tumor-associated peptides (TUMAPs) confirmed to be naturally presented in human cancer tissue. We treated a total of 96 human leukocyte antigen A (HLA-A)*02(+) subjects with advanced RCC with IMA901 in two consecutive studies. In the phase 1 study, the T cell responses of the patients to multiple TUMAPs were associated with better disease control and lower numbers of prevaccine forkhead box P3 (FOXP3)(+) regulatory T (T-reg) cells. The randomized phase 2 trial showed that a single dose of cyclophosphamide reduced the number of T-reg cells and confirmed that immune responses to multiple TUMAPs were associated with longer overall survival. Furthermore, among six predefined populations of myeloid-derived suppressor cells, two were prognostic for overall survival, and among over 300 serum biomarkers, we identified apolipoprotein A-I (APOA1) and chemokine (C-C motif) ligand 17 (CCL17) as being predictive for both immune response to IMA901 and overall survival. A randomized phase 3 study to determine the clinical benefit of treatment with IMA901 is ongoing.

引用

页码：1254 / +

页数：23

共 74 条

[11]

Brossart P, 2001, CANCER RES, V61, P6846

[12]

Burger Danielle, 2002, Autoimmunity Reviews, V1, P111, DOI 10.1016/S1568-9972(01)00018-0

[13] Phenotypical and functional specialization of FOXP3+ regulatory T cells [J].

Campbell, Daniel J. ;

Koch, Meghan A. .

NATURE REVIEWS IMMUNOLOGY, 2011, 11 (02) :119-130

[14] MAGE-Al-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma [J].

Chianese-Bullock, KA ;

Pressley, J ;

Garbee, C ;

Hibbitts, S ;

Murphy, C ;

Yamshchikov, G ;

Petroni, GR ;

Bissonette, EA ;

Neese, PY ;

Grosh, WW ;

Merrill, P ;

Fink, R ;

Woodson, EMH ;

Wiernasz, CJ ;

Patterson, JW ;

Slingluff, CL .

JOURNAL OF IMMUNOLOGY, 2005, 174 (05) :3080-3086

[15] Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas [J].

Dengjel, Jorn ;

Nastke, Maria-Dorothea ;

Gouttefangeas, Cecile ;

Gitsioudis, Gitsios ;

Schoor, Oliver ;

Altenberend, Florian ;

Mueller, Margret ;

Kraemer, Bjoern ;

Missiou, Anna ;

Sauter, Martina ;

Hennenlotter, Joerg ;

Wernet, Dorothee ;

Stenzl, Arnulf ;

Rammensee, Hans-Georg ;

Klingel, Karin ;

Stevanovic, Stefan .

CLINICAL CANCER RESEARCH, 2006, 12 (14) :4163-4170

[16] Pretreatment frequency of circulating IL-17+CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients [J].

Derhovanessian, Evelyna ;

Adams, Victoria ;

Haehnel, Karin ;

Groeger, Andrea ;

Pandha, Hardev ;

Ward, Stephen ;

Pawelec, Graham .

INTERNATIONAL JOURNAL OF CANCER, 2009, 125 (06) :1372-1379

[17] Sorafenib in advanced clear-cell renal-cell carcinoma [J].

Escudier, Bernard ;

Eisen, Tim ;

Stadler, Walter M. ;

Szczylik, Cezary ;

Oudard, Stephane ;

Siebels, Michael ;

Negrier, Sylvie ;

Chevreau, Christine ;

Solska, Ewa ;

Desai, Apurva A. ;

Rolland, Frederic ;

Demkow, Tomasz ;

Hutson, Thomas E. ;

Gore, Martin ;

Freeman, Scott ;

Schwartz, Brian ;

Shan, Minghua ;

Simantov, Ronit ;

Bukowski, Ronald M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :125-134

[18] Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial [J].

Escudier, Bernard ;

Eisen, Tim ;

Stadler, Walter M. ;

Szczylik, Cezary ;

Oudard, Stephane ;

Staehler, Michael ;

Negrier, Sylvie ;

Chevreau, Christine ;

Desai, Apurva A. ;

Rolland, Frederic ;

Demkow, Tomasz ;

Hutson, Thomas E. ;

Gore, Martin ;

Anderson, Sibyl ;

Hofilena, Gloria ;

Shan, Minghua ;

Pena, Carol ;

Lathia, Chetan ;

Bukowski, Ronald M. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (20) :3312-3318

[19] Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor based antitumor vaccine [J].

Filipazzi, Paola ;

Valenti, Roberta ;

Huber, Veronica ;

Pilla, Lorenzo ;

Canese, Paola ;

Iero, Manuela ;

Castelli, Chiara ;

Mariani, Luigi ;

Parmiani, Giorgio ;

Rivoltini, Licia .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18) :2546-2553

[20] Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients [J].

Finke, James H. ;

Rini, Brian ;

Ireland, Joanna ;

Rayman, Patricia ;

Richmond, Amy ;

Golshayan, Ali ;

Wood, Laura ;

Elson, Paul ;

Garcia, Jorge ;

Dreicer, Robert ;

Bukowski, Ronald .

CLINICAL CANCER RESEARCH, 2008, 14 (20) :6674-6682

← 1 2 3 4 5 6 7 8 →